Similarly, Mehdizadeh et al
Retatrutide is an investigational medicinal product (IMP) accessible only through authorised clinical trials
At 3 months, none were on prandial insulin and at 10 months, seven were off insulin
The FDA reports include nausea, vomiting, diarrhea, abdominal pain, constipation, injection site reactions, and more severe outcomes including pancreatitis requiring hospitalization, gallbladder disease, severe hypoglycemia, and acute kidney injury
Between 2021 and 2024, semaglutide-based weight loss therapy evolved from a specialty treatment to mainstream demand, creating widespread shortages and access barriers
Determinants of the development of post-traumatic stress disorder, in the general population